Xando Díaz-Villamarín

9PUBLICATIONS
20CO-AUTHORS
PharmacogenomicsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMedical bacteriologyGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jun 26, 2026
Pharmacokinetic/Pharmacodynamic Modelling of Cefquinome in Lactating Sheep and Lactating Goats After Intravenous, Subcutaneous and Long-Acting Administrations.

|Mar 14, 2026
The Early Safety Signal of Sacituzumab Govitecan-Related Toxicity and the UGT1A1*28 Genotype in Metastatic Breast Cancer: A Real-World Preliminary Report.

María Martínez-Pérez, María Teresa Nieto-Sánchez, Xando Díaz-Villamarín

|Jun 25, 2025
Clinical Pharmacogenetics: Results After Implementation of Preemptive Tests in Daily Routine.

Xando Díaz-Villamarín, María Martínez-Pérez, María Teresa Nieto-Sánchez

|Feb 18, 2025
The relationship between gut and nasopharyngeal microbiome composition can predict the severity of COVID-19.

Benita Martin-Castaño, Patricia Diez-Echave, Jorge García-García

|Nov 09, 2024
Selective Digestive Decontamination: A Comprehensive Approach to Reducing Nosocomial Infections and Antimicrobial Resistance in the ICU.

María Martínez-Pérez, Rosario Fernández-Fernández, Rocío Morón

|Jul 27, 2024
Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with Fluoropyrimidines: An Observational Study.

Xando Díaz-Villamarín, María Martínez-Pérez, María Teresa Nieto-Sánchez

Pageof 2

Frequent Collaborators

5 joint publications

Emilio Fernández-Varón

4 joint publications

José Cabeza-Barrera

4 joint publications

Rocío Morón-Romero

3 joint publications

Ana Pozo-Agundo